Hunter Immunology starts national lung disease vaccine trial
Scientists at Hunter Immunology have developed a treatment for Chronic Obstructive Pulmonary Disorder, or COPD, which is being trialled on up to 340 patients at major hospitals around the country.
Recruitment is now underway at 23 sites, including The Austin Hospital, The Alfred and the Royal Melbourne in Victoria, St Vincents Hospital and the Prince of Wales Hospitals in Sydney and both Royal Brisbane and Royal Perth Hospitals.
The drug HI 164OV is taken orally and works by stimulating the immune system to alleviate the flare ups commonly occurring in patients with moderate to severe disease.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.